The ongoing TWINPEAK study evaluates the drug's safety and efficacy across several gastrointestinal cancers, with initial data presented at the 2026 American Society of Clinical Oncology meeting. Researchers observed promising signals at the 2 mg/kg dose level, while the 3 mg/kg cohort continues to provide safety and tolerability metrics. Topline results for this specific pancreatic cancer group are expected by the end of 2026.

Spevatamig functions as an innate immunity enhancer, a class of drugs designed to activate macrophages and dendritic cells to target "cold tumors" that typically evade traditional immune checkpoint inhibitors. According to CEO Ming Wang, the molecule was engineered in San Diego to avoid the hematological toxicity that hindered earlier CD47-targeting therapies. Given its orphan drug and Fast Track designations from the FDA, the company views this trial as a potential turning point for patients facing limited treatment options beyond systemic chemotherapy.